Nelotanserin is a novel once-daily oral 5HT2A inverse agonist. The 5HT2A receptor has been associated with neuropsychiatric effects, including visual hallucinations.
Researchers found that nursing homes enrolled in the OASIS program had a 7.6% drop in antipsychotic prescriptions, compared with a 3.9% decline at the other nursing homes.
The research team used hypertonic saline to induce the release of arginine-vasopressin, with each patient's blood then tested for arginine-vasopressin.
Second-generation antipsychotic agents, used for the treatment of schizophrenia and major depressive disorder (MDD), are associated with varying degrees of activating or sedating adverse effects (AEs), with some agents having both properties.
Otsuka and Lundbeck announced that the Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the expanded labeling of Abilify Maintena (aripiprazole extended-release) for the maintenance treatment of bipolar I disorder in adults.
A batch of antiretroviral drug labels has been updated to include Contraindications with an antidepressant.
New research published in Chest indicates that use of antipsychotic medications may be associated with a higher risk of pneumonia in patients with Alzheimer's disease.
A study in the Journal of Clinical Psychopharmacology found that overall use of long-acting injectable antipsychotics for the treatment of schizoaffective disorder was low, and adherence to antipsychotics was suboptimal among these patients in the real-world setting.
Alkermes announced that it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a two-month dosing interval of Aristada (aripiprazole lauroxil), providing a third dosing option for the treatment of schizophrenia.
Memories of delusions in the intensive care unit are composed of a mixture of fact and fiction, and are not dependent on the presence of delirium, according to a study published online July 26 in the Journal of Clinical Nursing.
An analysis published in International Clinical Psychopharmacology found that paliperidone palmitate once-monthly (PP1M) had a more favorable benefit-risk profile compared to oral paliperidone extended-release (ER) in the maintenance treatment of schizophrenia through Week 40.
Co-treatment with topiramate and an antipsychotic significantly decreased total, positive, negative, and general psychopathology and weight/body mass index (BMI) in patients with schizophrenia spectrum disorder while being well tolerated, a meta-analysis in the Journal of Clinical Psychology reported.